Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
about
Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia.Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients.Prognostic impact of CD200 and CD56 expression in pediatric B-cell acute lymphoblastic leukemia patients.
P2860
Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@en
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@nl
type
label
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@en
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@nl
prefLabel
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@en
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@nl
P2093
P2860
P356
P1476
Evaluation of new markers for ...... acy of MRD 2016; 00B: 000-000.
@en
P2093
Asma R Bibi
Brijesh Arora
Gaurav Chatterjee
Nikesh Kunder
Nilesh Deshpande
Nisha Ghatwai
Papagudi G Subramanian
Prashant R Tembhare
Prathibha Amare
Shripad Banawali
P2860
P304
P356
10.1002/CYTO.B.21486
P577
2016-10-07T00:00:00Z